MedTrace Logo

Open-Label Extension and Safety Study of Talazoparib

NCT02921919 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2022-08-24

Study results available
· View outcomes & findings →

Summary

This is a single-arm, open-label, extended treatment, safety study in patients treated with talazoparib in qualifying studies.

Conditions

Interventions

DRUG

Talazoparib

Maximum starting dose: 1mg/day or last tolerated dose in the originating protocol

Sponsors & Collaborators

  • Medivation, Inc.

    collaborator INDUSTRY

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-08
Primary Completion
2021-07-20
Completion
2021-07-20

Countries

  • United States
  • Canada
  • France
  • Germany
  • Hungary
  • Moldova
  • Poland
  • Russia
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02921919 on ClinicalTrials.gov